If you have been reading about TB-500 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-24. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
The cyclopropenium ion is the cation with the formula C3H+3. It has attracted attention as the smallest example of an aromatic cation. Its salts have been isolated, and many derivatives have been characterized by X-ray crystallography. The cation and some simple derivatives have been identified in the atmosphere of the Saturnian moon Titan.
During the Second World War, Nazi Germany effectively enslaved about 12 million people, both those considered undesirable and citizens of conquered countries, with the avowed intention of treating these Untermenschen (sub-humans) as a permanent slave-class of inferior beings who could be worked until they died, and who possessed neither the rights nor the legal status of members of the Aryan race. Besides Jews, the harshest deportation and forced labour policies were applied to the populations of Poland, Belarus, Ukraine, and Russia. By the end of the war, half of Belarus' population had been killed or deported.
== Honours and awards == Commonwealth Scholar at Trinity College, Cambridge, 1960-1963 Powell Prize for English Verse, Trinity College, 1961 Vidya Jyothi from the President of Sri Lanka, 1992 Honorary DLitt, Sōka University (Japan), 1996 Doctor of Science (honoris causa), University of Ruhuna, Sri Lanka, 2004 Visiting By-Fellowship, visiting scholar, Churchill College, Cambridge, England 2015/16 Ada Derana Sri Lankan of the Year 2017 - Global Scientist Wickramasinghe was appointed Member of the Order of the British Empire (MBE) in the 2022 New Year Honours for services to science, astronomy and astrobiology.
Sources: en.wikipedia.org
This is seen with the subcutaneous injection of triptans for migraine headache, medroxyprogesterone acetate for contraception, as well as many monoclonal antibodies. In most cases, injection site reactions are self-limiting and resolve on their own after a short time without treatment, and do not require the medication to be discontinued. The administration of vaccines subcutaneously is also associated with injection site reactions. This includes the BCG vaccine which is associated with a specific scar appearance which can be used as evidence of prior vaccination. Other subcutaneous vaccines, many of which are live vaccines including the MMR vaccine and the varicella vaccine, which may cause fever and rash, as well as a feeling of general malaise for a day or two following the vaccination.
The first 16 months of the MD program, the preclerkship phase, consists of fundamental scientific and medical coursework. Multi-semester courses include bioethics and service learning. This is followed by a 12-month clinical phase that includes clerkships and preparation for and completion of the United States Medical Licensing Examination (USMLE) Step 1. Clerkships are followed by completion of the USMLE Step 2 exam. The final 18 months of medical school include clinical electives, increased clinical duties, and a research capstone project. In addition to Jacobi and Montefiore hospitals, medical students can train in medical facilities such as the VA Bronx Healthcare System and Bronx Psychiatric Center. Students may also volunteer at the Einstein Community Health Outreach (ECHO) Free Clinic, which provides care to those without health insurance. Founded in 1999, ECHO was the first such clinic in New York City and one of the first in the United States.
"I had the original idea of how the machine would work and it was my patent, but it was a joint effort getting it to work in a saleable form. It was 3 years of very hard work. I had originally studied heavy electrical engineering before changing over to Medical School and qualifying as a Medical Doctor in 1968. In fact I was Senior House (Casualty) Officer (A&E or ER) in 1970 at North Manchester General Hospital when I filed the patent. I must have been the only hospital doctor in Britain with an oscilloscope, a soldering iron and a drawing board in his room in the Doctors' Residence. The housekeepers were bemused by all the wires. Frank originally trained as a Banker but quit to take a job with a local electronics firm during the development. He died in 1987, a terrible loss." [Extract from personal communication received in March 2010 from John Kirby.]
=== Amino acid substitution === Incorporating amino acids that deviate from the genetic code predictions is usually detected as amino acid substitutions in proteins and peptides. Such alternate RNA decoding results in stable and abundant proteins in both mouse and human tissues. The abundance of such substitutions is determined by multiple mechanisms, including codon frequency, codon–anticodon mismatches, RNA modifications, and protein stability. In some cells certain amino acids can be depleted and thus affect translation efficiency. For instance, activated T cells secrete interferon-γ which triggers intracellular tryptophan shortage by upregulating the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme. Despite tryptophan depletion, in-frame protein synthesis continues across tryptophan codons. This is achieved by incorporation of phenylalanine instead of tryptophan. The resulting peptides are called W>F "substitutiant". Such W>F substitutiant are abundant in certain cancer types and have been associated with increased IDO1 expression. Functionally, W>F substitutiants can impair protein activity.
Sources: en.wikipedia.org
==== Gabasync ==== Gabasync, a treatment consisting of a combination of gabapentin and two other medications (flumazenil and hydroxyzine) as well as therapy, is an ineffective treatment promoted for methamphetamine addiction. It had also been claimed to be effective for dependence on alcohol or cocaine. It was marketed as PROMETA. While the FDA has approved individual drugs, they have not approved their off-label use for addiction treatment. Gabasync was marketed by Hythiam, Inc., which is owned by Terren Peizer, a former junk bond salesman who has since been convicted of securities fraud relative to another company. Hythiam charges up to $15,000 per patient to license its use (of which half goes to the prescribing physician, and half to Hythiam). In a November 2005 article entitled "Curb Your Cravings For This Stock", Barrons wrote: "If the venture works out for patients and the investing public, it'll be a rare success for Piezer, who's promoted a series of disappointing small-cap medical or technology stocks ... since his days at Drexel". 60 Minutes, NBC News, and The Dallas Morning News criticized Peizer after the company bypassed clinical studies and government approval when bringing to market Prometa; the addiction drug proved to be completely ineffective. CBS News journalist Scott Pelley said to Peizer in 2007: "Depending on who you talk to, you're either a revolutionary or a snake oil salesman." Journalist Adam Feuerstein opined: "most of what Peizer says is dubious-sounding hype".
=== Clean energy roll-back === The bill was described by The New York Times as derailing renewable energy production and research in the United States, and possibly ceding the clean energy race to China. Its policies favor fossil fuel companies over renewable energy such as solar, wind, and EV manufacturing, and are expected to lead to large clean energy job losses, factory closures, and deter investment in clean technologies. Specifically, the law phases out most clean-energy tax incentives introduced under the Biden-era Inflation Reduction Act such as credits for low-carbon electricity (wind, solar), electric vehicle rebates, home electrification, clean hydrogen, and domestic manufacturing of batteries and solar panels. The law rescinds various IRA funds for grants related to freeway removal improving biking and walking in poorer neighborhoods, electric truck and bus manufacturing, faster state and local environmental reviews and place-based green industrial policy and home electrification. An April 2026 study projected the IRA's impact on clean energy investments would be nearly wiped out by the OBBBA, and emissions would be reduced by only 34 percent below 2005 levels, compared to 44 percent with the IRA. A report released by environmental group BlueGreen Alliance found that the OBBBA caused 223 manufacturing and clean energy projects to stall or be cancelled, affecting over 111,000 jobs and $82.9 billion in investment.
=== Alleged censorship of criticism of Donald Trump and Jeffrey Epstein === In 2026 TikTok was criticized for allegedly censoring criticism of Donald Trump and references to Jeffrey Epstein, with whom Trump had a long-standing relationship. California governor Gavin Newsom said the Government of California was launching an investigation of TikTok for violating California law by censoring Trump-critical content. TikTok claimed it was not deliberately censoring content and blamed alleged power outages.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.